Regional patterns of 18F-florbetaben uptake in presenilin 1 mutation carriers

• Published in: Neurobiology of aging Vol. 81; pp. 1 - 8
• Main Authors: Sala-Llonch, Roser, Falgàs, Neus, Bosch, Beatriz, Fernández-Villullas, Guadalupe, Balasa, Mircea, Antonell, Anna, Perissinotti, Andres, Pavía, Javier, Campos, Francisco, Lladó, Albert, Lomeña, Francisco, Sánchez-Valle, Raquel
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2019
• Subjects: Adult; Alzheimer Disease - diagnostic imaging; Alzheimer Disease - genetics; Alzheimer Disease - metabolism; Alzheimer's disease; Amyloid; Amyloid beta-Peptides - metabolism; Aniline Compounds - metabolism; Biomarkers; Cerebral Cortex - diagnostic imaging; Cerebral Cortex - metabolism; Familial Alzheimer's disease; Female; Florbetaben; Fluorine Radioisotopes - metabolism; Heterozygote; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; PET; Positron-Emission Tomography; Presenilin 1; Presenilins - genetics; Radiopharmaceuticals - metabolism; Stilbenes - metabolism; Florbetaben; Presenilin 1; Biomarkers; Familial Alzheimer's disease; Amyloid; Alzheimer's disease; PET
• ISSN: 0197-4580; 1558-1497; 1558-1497
• DOI: 10.1016/j.neurobiolaging.2019.04.010

Individuals with autosomal dominant Alzheimer's disease (ADAD) present amyloid deposits before symptoms onset. We aimed to investigate efficacy and safety of 18F-florbetaben (FBB) for assessing amyloid deposition in ADAD. We acquired FBB positron emission tomography and magnetic resonance imaging of 25 individuals from PSEN1 families (NCT02362880). We studied individual uptake patterns, group differences, and correlation with estimated years to symptoms onset, as well as adverse events. We found that asymptomatic carriers (N = 14) showed increased FBB uptake across the cerebral cortex and in the caudate. FBB accumulation appeared more than 15 years before onset in the precuneus and bankssts, among other regions, overlapping regions showing increased cortical thickness in the same subjects. FBB uptake correlated with estimated years to symptoms onset in several areas, especially the rostral anterior cingulate. Symptomatic carriers (N = 7) had an elevated FBB uptake plateau. No adverse events were reported. Overall, we found progressive FBB uptake in ADAD starting 2 decades before symptoms. The rostral anterior cingulate is a candidate area to track Aβ deposition in addition to the precuneus. •FBB-PET is safe in ADAD and useful to track amyloid progression.•PSEN1 carriers showed progressive amyloid uptake.•Amyloid uptake starts 15 years before onset in cortical areas and in the caudate.•The rostral anterior cingulate can track disease progression in ADAD.•Amyloid uptake coincides with increased cortical thickness.